65894-41-9

Basic information

• Product Name: Daturabietatriene
• Synonyms: Daturabietatriene
• CAS NO: 65894-41-9
• Molecular Formula: C20H30O2
• Molecular Weight: 302.451
• Mol File: 65894-41-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Daturabietatriene(CAS DataBase Reference)
• NIST Chemistry Reference: Daturabietatriene(65894-41-9)
• EPA Substance Registry System: Daturabietatriene(65894-41-9)

Safety Data

• Hazardous Substances Data: 65894-41-9(Hazardous Substances Data)

Usage

General Description

Daturabietatriene is a type of tropine alkaloid that is found in the toxic plant Datura stramonium, also known as jimsonweed. It is a bicyclic terpenoid compound and is responsible for the hallucinogenic and toxic effects of the plant. Daturabietatriene acts as a competitive antagonist at muscarinic acetylcholine receptors in the central and peripheral nervous system, leading to symptoms such as blurred vision, dilated pupils, dry mouth, and confusion. Ingestion of Datura stramonium can result in severe toxicity and even death, making it important to handle the plant with caution and avoid consumption.

Upstream product

• 29461-23-2 15-hydroxydehydroabietic acid methyl ester 
• 54113-95-0 15-hydroxydehydroabietic acid 
• 514-10-3 abietic acid 
• 19402-34-7 methyl abieta-8,13⁽¹⁵⁾-dien-18-oate 
• 19402-33-6 abieta-8,13⁽¹⁵⁾-dien-18-oic acid 

Relevant articles and documents

Design and synthesis of tricyclic terpenoid derivatives as novel PTP1B inhibitors with improved pharmacological property and in vivo antihyperglycaemic efficacy

Overexpression of protein tyrosine phosphatase 1B (PTP1B) induces insulin resistance in various basic and clinical research. In our previous work, a synthetic oleanolic acid (OA) derivative C10a with PTP1B inhibitory activity has been reported. However, C10a has some pharmacological defects and cytotoxicity. Herein, a structure-based drug design approach was used based on the structure of C10a to elaborate the smaller tricyclic core. A series of tricyclic derivatives were synthesised and the compounds 15, 28 and 34 exhibited the most PTP1B enzymatic inhibitory potency. In the insulin-resistant human hepatoma HepG2 cells, compound 25 with the moderate PTP1B inhibition and preferable pharmaceutical properties can significantly increase insulin-stimulated glucose uptake and showed the insulin resistance ameliorating effect. Moreover, 25 showed the improved in vivo antihyperglycaemic potential in the nicotinamide–streptozotocin-induced T2D. Our study demonstrated that these tricyclic derivatives with improved molecular architectures and antihyperglycaemic activity could be developed in the treatment of T2D.

8. 11, 13 - Lohans Pinaceae - 13 - ol and intermediate preparation method (by machine translation)

The present invention discloses a process for preparing compound 9 shown 8, 11, 13 - Lohans Pinaceae - 13 - alcohol, or its pharmaceutically acceptable salt, or its solvate of the method, the method comprises the following steps: h, in the presence of oxidizing agent and acid, in order to compound 8 as raw material preparation to obtain compound 9; wherein oxidizing agent selected from hydrogen peroxide or over-tertiary butyl alcohol, acid selected from H2 SO4 , Toluenesulfonates. Process for making a compound of the present invention 9 of the method, the method is simple, high yield, easy to enlarge, and is suitable for industrial large-scale production. (by machine translation)